Bristol-Myers Squibb Company (BMY) announced an update on their ongoing clinical study.

Bristol-Myers Squibb is running a late stage study that pits its multiple sclerosis drug ozanimod against fingolimod in young patients with relapsing remitting MS. The goal is to see if ozanimod can match or beat fingolimod on effectiveness and safety, which would expand BMY’s reach into a niche but strategic part of the MS market.

The study tests oral ozanimod against oral fingolimod, both already used in adult MS care. Ozanimod aims to offer similar or better control of relapses with a cleaner safety and dosing profile, which could support broader use and stronger pricing power if results are positive.

The trial uses a randomized, parallel group setup with both patients and doctors blinded to which drug is given. This design helps keep results unbiased and makes any difference in outcomes between ozanimod and fingolimod more convincing for regulators and investors.

The study was first submitted on 2024-04-25 and is now in recruiting status. The last update on 2026-09-09 signals active management of the trial and keeps investors informed that timelines and assumptions for ozanimod in MS remain in play.

For BMY, a strong readout could support long term revenue in neurology and improve sentiment toward its pipeline, partly offsetting pressure in more crowded oncology lines. Investors will watch how this stacks up against other MS players like NVS and BIIB, since pediatric data can shape guideline trends and future market share.

The study remains ongoing and updated, with more detailed information available on the ClinicalTrials portal.

To learn more about BMY’s potential, visit the Bristol-Myers Squibb Company drug pipeline page.